Challenges in Von Hippel–Lindau’s disease: PRRT in patients on hemodialysis
Von Hippel–Lindau’s disease (VHL) is a hereditary tumor syndrome characterized by its prototype lesions, hemangioblastomas, and renal cell carcinomas. Treatment for renal cell carcinomas can ultimately result in long-term dialysis. Pancreatic neuroendocrine tumors (pNET) can also occur in the course of the disease. Currently, peptide receptor radionuclide therapy (PRRT) is the standard treatment for progressive neuroendocrine tumors. However, little is known about treatment with PRRT in patients on dialysis, an infrequent presentation in patients with VHL. We present a 72-year-old man with VHL... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2022 |
Schlagwörter: | Adolescent/young adult / Male / White / Netherlands / Kidney / Endocrine-related cancer / Nephrology / Oncology / Radiology/Rheumatology / Insight into disease pathogenesis or mechanism of therapy / March / 2022 / Internal Medicine / Endocrinology / Diabetes and Metabolism / Journal Article |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27612789 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://dspace.library.uu.nl/handle/1874/446053 |